Opko Health vs Travere Therapeutics
Opko Health is the larger business, with $607m of revenue in fiscal 2025 against $491m for Travere Therapeutics (1.2 times as much). Travere Therapeutics grew faster (110.5% against -14.9%). Travere Therapeutics kept more of each dollar of sales as profit: a net margin of -5.2% against -37.2%.
| Latest fiscal year | Opko HealthOPK, 2025 | Travere TherapeuticsTVTX, 2025 |
|---|---|---|
| Revenue | $607m | $491m |
| Revenue growth | -14.9% | 110.5% |
| Net income | −$226m | −$25.5m |
| Operating margin | -19.3% | — |
| Net margin | -37.2% | -5.2% |
| Return on equity | -17.1% | -29.4% |
| Free cash flow | −$191m | $37.8m |
| Cash | $364m | $93.0m |
| Total debt | $344m | $312m |
| Debt to equity | 27.1% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $47.0m | — |
| Employees | 2,275 | 497 |
| Market value | $1.30bn | $4.71bn |
| Price vs our value range | — | — |
| Moat score | 21 (Weak) | 36 (Weak) |
| Insider trades, 12 months | 33 buys, 0 sales | 0 buys, 119 sales |